BlueBird

Bluebird bio, Inc., a clinical-stage company committed to  T cell-based immuno-therapies, today announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock at a public offering price of $170.00 per share, for the gross proceeds of $500 Million. The firm would use the proceeds of this offering primarily to advance its […]